• Home
  • Jaakko M Itkonen
Jaakko M Itkonen

Jaakko M Itkonen
Celltrion Healthcare Finland Oy · Nordic Countries - Division of European Business

Doctor of Pharmacy

About

10
Publications
6,598
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
384
Citations
Additional affiliations
March 2015 - October 2020
University of Helsinki
Position
  • PhD Student
Description
  • Doctoral studies on the ocular use of protein therapeutics
Education
March 2015 - October 2020
University of Helsinki
Field of study
  • Biopharmacy
August 2010 - September 2014
University of Helsinki
Field of study
  • Biopharmacy

Publications

Publications (10)
Article
Full-text available
Pharmaceutical proteins, compared to small molecular weight drugs, are relatively fragile molecules, thus necessitating monitoring protein unfolding and aggregation during production and post-marketing. Currently, many analytical techniques take offline measurements, which cannot directly assess protein folding during production and unfolding durin...
Article
Full-text available
Ciliary neurotrophic factor (CNTF) is one of the most studied neuroprotective agents with acknowledged potential in treating diseases of the posterior eye segment. Although its efficacy and mechanisms of action in the retina have been studied extensively, it is still not comprehensively understood which retinal cells mediate the therapeutic effects...
Article
Full-text available
Time-Gated Surface-Enhanced Raman spectroscopy (TG-SERS) was utilized to assess recombinant protein production in Escherichia coli. TG-SERS suppressed the fluorescence signal from the biomolecules in the bacteria and the culture media. Characteristic protein signatures at different time points of the cell cultivation were observed and compared to c...
Article
The purpose of this study was to produce poly(DL-lactic-co-glycolic acid) (PLGA) – based microparticles (MPs), externally decorated with hyaluronic acid (HA). The MPs are intended for intravitreal injections in the treatment of posterior eye segment and have been designed to prolong the release of growth factors into the vitreous body, therefore ai...
Article
Full-text available
The use of living cells for the synthesis of pharmaceutical proteins, though state-of-the-art, is hindered by its lengthy process comprising of many steps that may affect the protein's stability and activity. We aimed to integrate protein expression, purification, and bioconjugation in small volumes coupled with cell free protein synthesis for the...
Article
Full-text available
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF anti...
Conference Paper
Full-text available
Neurotrophic factors participate in regulating the differentiation, proliferation, survival and death of neuronal cells within the central nervous system. Human ciliary neurotrophic factor (hCNTF) has neuroprotective properties and influences energy balance. The therapeutic potential of hCNTF consequently ranges from neurodegenerative diseases, suc...
Article
Full-text available
Background: Neurotrophic factors influence survival, differentiation, proliferation and death of neuronal cells within the central nervous system. Human ciliary neurotrophic factor (hCNTF) has neuroprotective properties and is also known to influence energy balance. Consequently, hCNTF has potential therapeutic applications in neurodegenerative, ob...

Network

Cited By

Projects

Projects (2)
Project
The purpose of our project is to develop a streamlined in-line in vitro technology for the development and testing of biological drugs. Expected outcomes: - We will build the first module as a stand-alone device for pharmaceutical protein preparation and subsequent screening, and the community around it. - We will include in-line process control for stringent quality control of the final product. While our project is limited to the development of biological drugs, and only the first module for a larger protocol and device: Integrated Continuous Protein and Conjugation Synthesis (IC-PCS), the results of this project will ultimately be applicable to all of biotechnology. In addition, it will also strengthen international collaboration and build a research community around the concept of IC-PCS
Archived project
This work is focused on the integration of existing technologies to streamline and simplify the screening and targeting of pharmaceutically relevant proteins by developing a cell-free platform technology. This platform is designed for the generic screening of both biosynthetic pathway enzymes and pharmaceutical proteins, with an emphasis on the development of biological drugs for the treatment of degenerative eye diseases such as AMD.